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Abstract
Background: HIV affects the central nervous system resulting in HIV associated neurocognitive impairment (NCI) in
approximately 50% of people living with HIV. It typically affects memory, learning, working memory, fine motor
skills, speed of information processing, verbal fluency and executive functioning cognitive domains. NCI can affect
adherence to antiretroviral therapy (ART), employability, driving ability and activities of daily living. NCI is not
routinely screened for in Zimbabwe, and the burden is not known in this setting. The objectives of this study were:
1) To determine NCI prevalence using a comprehensive neuropsychological battery at two primary health care
clinics in Harare; 2) To assess the pattern of cognitive impairment across cognitive domains using a gold standard
neuropsychological (NP) battery in HIV-positive patients compared to HIV-negative controls.
Methods: Inclusion criteria: 18 years or older; minimum 7 years education; no neurological or psychiatric disorders.
HIV-positive participants were on ART for ≥3 months; HIV-negative participants had a confirmed HIV negative status
in the past month. A comprehensive NP battery, functional assessments, demographic and medical history
questionnaires were administered. The NP battery consisted of tests assessing memory, learning, working memory,
fine motor skills, speed of information processing, verbal fluency and executive functioning.
Results: Two-hundred-and-thirty-one participants were recruited. Of those, 155 were HIV-positive (Female = 70%,
Age M = 37.8; SD 11.2) and 76 HIV-negative (Female = 63%, Age M = 31.2; SD 9.9). HIV-positive participants were on
ART for an average of 6 years. NCI was present in 49.7% HIV positive participants. Compared to HIV-negative
participants, the HIV-positive group had significantly poorer scores in 5 out of 7 cognitive domains. A good level of
education is negatively correlated with NCI.
Conclusions: NCI prevalence in HIV-positive population Zimbabwe is consistent with global estimates. NCI persists
in adults who are on ART. Routine assessment of NCI in adults attending primary care clinics using this adapted
battery is therefore important so that they are identified early and are provided the necessary interventions.
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Background
HIV prevalence in Zimbabwe is 13.3%, among the high-
est globally, with women affected more than men [1].
While HIV affects many organs [2], HIV enters the brain
[3, 4] almost immediately after systemic infection [5].
This can lead to neurocognitive impairment (NCI) also
known as HIV-associated neurocognitive disorders
(HAND) [6–8] even among those without detectable
virus. Antiretroviral therapy (ART) is now widely access-
ible to people living with HIV (PLWH) and among
people who know their HIV status in Zimbabwe 87% are
on treatment [9]. PLWH who are virally suppressed be-
cause of good medication adherence can have a nearly
normal life span [10]. However, despite this positive out-
come NCI has been detected in up to 50% of PLWH
who are on ART [3] and it continues to be common in
advanced HIV infection [11, 12]. HIV- associated NCI
prevalence has been estimated to be between 35 to 70%
in Sub-Saharan Africa [13–15] Prevalence rates for HIV-
associated NCI in Zimbabwe are not known.
This high burden of NCI is of public health concern.
It negatively affects medication adherence, employment,
and activities of daily living [16–18]. ART adherence of
between 80 and 90% is required for PLWH to achieve
viral suppression [19]. It is extremely important to iden-
tify people with NCI to help them achieve this. To iden-
tify people with NCI assessment of commonly affected
cognitive domains are required so that their cognitive
deficit can be characterised and the necessary interven-
tions can be implemented.
The gold-standard practice for assessing HIV-
associated NCI is a comprehensive neuropsychological
(NP) test battery [20, 21] comprised of a battery of nu-
merous tests to assess key cognitive domains - executive
function, working memory/attention, learning and mem-
ory, motor speed, language (verbal fluency), and speed of
information processing [22]. Administering these gold-
standard neuropsychological batteries requires highly
specialized personnel (i.e., neuropsychologists) to admin-
ister, score, and interpret results. Many neuropsycho-
logical tests used in the gold-standard batteries are
proprietary and copyrighted materials that are expensive,
and few are available from the publisher’s sub-Saharan
languages with country-specific norms. Consequently,
neuropsychological tests and services are rare in low-
and middle-income countries (LMIC) [23]. A recent
systematic review identified culturally appropriate
neuropsychological tests commonly used for NCI assess-
ment in sub-Saharan Africa [24]. These tests are often
adapted and translated to the local languages.
Using adapted tests relevant to the local context along
with appropriate norms or a good control group is key
to getting valid and reliable results [25, 26]. In
Zimbabwe the prevalence of NCI in adults attending
primary care clinics is unknown because no study has
previously used a comprehensive NP battery to assess
cognitive functioning in PLWH. A study by the AIDS
Clinical Trials Group [27] utilized brief tests of neuro-
psychological functioning as part of a multi-country
study but they did not report prevalence estimates for
NCI in Zimbabwe.
The objectives of this study are 1) to assess NCI using
a gold standard NP battery widely used in HIV research
and that had been adapted for Zimbabwe; and 2) to
compare test performance between people living with
and without HIV recruited from primary care clinics in
Harare, Zimbabwe. This study is the first in Zimbabwe
to use a comprehensive NP battery to assess NCI to de-
scribe the pattern of neurocognitive impairment seen in
Zimbabwean people living with HIV.
Methods
Setting
Participants were recruited from two City of Harare pri-
mary care clinics located in the western townships of
Harare, Zimbabwe. Both clinics offer free HIV testing,
counselling and antiretroviral therapy treatment.
Participants
Participants were identified in two ways at the time they
presented to the clinic for their routine HIV clinic care
visit and voluntary HIV testing during the period Janu-
ary 2018 to July 2018: 1) Research assistants distributed
information leaflets explaining the study to patients who
were interested in participating and those interested re-
ported to the research assistant’s study office; and 2) Fa-
cility staff, including counsellors who conducted HIV
testing and provided adherence counselling to patients
at the clinic, referred participants to the onsite research
assistant. The research assistant screened the potential
participant for eligibility using the following inclusion
criteria: Adults aged 18 and above; ability to provide
written informed consent; at least 7 years of education
(which is the primary level education in Zimbabwe);
documented HIV positive as per HIV test result in their
medical record book (experimental group) or negative
(control group) status. HIV-positive participants had to
be on ART for at least 3 months. Participants who had a
current psychiatric illness, neurological disorders that
affect cognition, history of head injury/trauma with 30
min loss of consciousness or hospitalization overnight,
current alcohol intoxication and history of alcohol abuse
as per score on Alcohol Use Disorder Identification Test
(AUDIT) of 8 and above, depression as per score of 11
and above on Patient Health Questionnaire-9 (PHQ-9)
and those the interviewer assessed as too unwell and/or
too agitated to take part were excluded from the study.
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Measures
Screening: Participants were screened using an eligibility
criteria questionnaire which consists of yes/no state-
ments that address the inclusion and exclusion criteria.
The PHQ-9 and AUDIT questionnaires were also ad-
ministered in the screening process. Eligible participants
then proceeded to complete the rest of the question-
naires administered on the Research Electronic Data
Capture (RedCap) database in offline mode. REDCap
(Research Electronic Data Capture) is a secure, web-
based software platform designed to support data cap-
ture for research studies [28, 29]. The questionnaires
comprised of a medical history form, sociodemographic
details, and a self-report adherence questionnaire.
Neuropsychological battery tests and training
After screening, eligible participants were booked for
neuropsychological testing within 2 weeks of screening.
Each participant received a reminder text message or
phone call for their appointment. The Gold standard
battery based on the HIV Neurobehavioral Research
Centre (HNRC) University of California San Diego was
administered. This battery has been used in other similar
southern African settings for example Zambia [13] and
Botswana [30]. Clinical neuropsychologist (HG) trained
the first author (PN) a research psychologist in neuro-
psychological testing. This one-week training program
consisted of in-depth training in each test addressing
test administration rules and NP testing techniques. PN
then trained two research assistants (clinical psychology
interns at the research site) who had prior experience of
neuropsychological testing. PN together with the trained
research assistants, administered the neuropsychological
tests to participants enrolled in the study. NP testing
supervision was provided by HG via skype calls during
the study period. Data collected were entered into the
RedCap database.
NP testing took on average 2.5 h and the participant
could ask for a break in between the tests. Test instruc-
tions were forward and back translated from English to
Shona, which is the most widely used local language in
Zimbabwe. Test instructions were translated from
English to Shona by a Psychologist with experience in
neuropsychology and back translation was conducted by
a linguist. The back translation was checked by PN and
discrepancies were discussed. Participants could choose
whether the battery was administered to them in Shona
or English. PN and all research assistants were fluent in
both languages. An adapted version of the Hopkins
Verbal Learning Test, used in South Africa [26], was
used. The NP battery consisted of tests on seven cogni-
tive domains. 1) Motor Functioning: Grooved pegboard
test assessing dominant and non-dominant hand motor
skills [31], Successive Finger Taps Test [32]; 2) Speed of
information Processing: Wechsler Adult Intelligent
Scale III Digit symbol coding [33], Wechsler Adult Intel-
ligent Scale III Symbol search [33], Trail Making Test
Part A [34], Color Trails 1 [35]; 3) Executive Function-
ing: Wisconsin Card Sorting Test: Computer Version 4
Research Edition [36], Color Trails 2 [35]; 4) Working
Memory: Paced Auditory Serial Addition Test [37],
Wechsler Memory Scale III Spatial Span forward and
backward [38], Wechsler Adult Intelligent Scale III Digit
Span forward and backward [38], 5) Learning: Hopkins
Verbal Learning Test [39]. Brief Visuo-spatial Memory
Test [40]; 6) Memory: Hopkins Verbal Learning Test
[39], Brief Visuo-spatial Memory Test [40]; 7) Verbal
Fluency: Category/Semantic Fluency [41].
Participants were provided with refreshments before
testing started. They were reimbursed for transport costs
at the end of the testing.
Data analysis
The sample size was calculated as follows:
n ¼ Z
2Sn 1‐Snð Þ
Δ2 pð Þ n ¼
1:962 0:80ð Þ 0:20ð Þ
0:12 0:40ð Þ n ¼ 154
n = sample size.
Z = 1.96.
Sn = sensitivity of the gold standard battery.
Δ = precision of 0.1.
p = prevalence of HAND.
A sample size calculation indicated that a sample of
231 will provide sufficient power. The HIV negative par-
ticipants were enrolled at a ratio of 1: 2. Stata version 14
was used for data analysis. The normative scores for the
NP standard battery were taken from the means and
standard deviations of the HIV negative controls. These
were used to determine z-scores for the HIV positive
participants. The z-scores from each of the tests admin-
istered were used to calculate t-scores for each test. The
t-scores were used to determine a deficit score for each
test and these scores were averaged to determine the
global deficit score (GDS) for each participant. The cut-
off for impairment was > = 0.5. Unpaired t-tests were
used to analyse the differences between the HIV-positive
and the HIV-negative control groups. The association
between NCI and a range of demographic variables was
examined using logistic regression.
Results
Of 319 screened patients, 231 a total of 231 participants
were recruited into the study and completed the NP
battery of tests. Of these, 155 were HIV-positive
(female = 70%, age mean = 37.8; SD = 11.2) and 76 HIV-
negative (Female = 63%, Age M = 31.2; SD = 9.9). The
HIV-positive participants were slightly older than the
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HIV-negative participants. HIV-positive participants had
been on ART for an average of six years (mean = 71.4
months, SD = 48.7 months). The HIV positive group is
older, less educated with a poorer employment status
and with differences in marital status. See Table 1 for
baseline characteristics.
Biomedical and medication characteristics of HIV-
positive participants are described in Table 2. The
majority of HIV-positive participants (98%) were on
first-line ART regimens and one third of the participants
had their medications switched to second line since
ART initiation.
Table 3 describes the test performance on individual
tests. The independent t test showed HIV-positive
participants’ performance on NP tests across cognitive
domains were significantly worse than HIV-negative par-
ticipants’ performance in the domains of Attention,
Speed of Information Processing, Learning, Memory and
Verbal Fluency (see Table 3) suggesting higher rates of
cognitive impairment in the HIV-positive group. With
regards to individual tests in the Executive Function do-
main the HIV-positive participants performed worse on
the Color Trails 2 (p = 0.001) test but there were no sta-
tistically significant differences on the Wisconsin Card
Sorting Tests. Similarly, in the motor function domain
differences were observed in the grooved pegboard tests
but no statistically significant differences were observed
in the successive finger tapping tests, dominant hand
(p = 0.65) and non-dominant hand (p = 0.28).
According to the global deficit scores calculation, 77
of the 155 (49.7%) HIV-positive participants had NCI.
Motor function was the least impaired as only 26.0%
were impaired. Memory and attention domains had
more than 50% of the HIV-positive patients impaired.
Figure 1 shows the distribution of cognitive impairment
across the domains.
Table 1 Baseline Characteristics
Characteristics HIV Positive N = 155 HIV Negative N = 76 p-
valueN % N %
HIV status
Negative 76 32.9%
Positive 155 67.1%
Sex 0.270
Male 46 29.7% 28 36.8%
Female 109 70.3% 48 63.2%
Age Group 0.010
18–25 31 20.0% 25 32.9%
26–45 82 52.9% 42 55.3%
46 and above 42 27.1% 9 11.8%
Marital Status 0.001
Married/partner 62 43.4% 41 55.4%
Divorced/widowed 47 32.9% 4 5.4%
Single 34 23.8% 29 39.2%
Completed Education 0.001
7 years 30 19.4% 8 10.5%
8 to 10 years 52 33.6% 11 14.5%
11 to 13 years 62 40.0% 35 46.1%
14 years and above 11 7.1% 22 29.0%
Current Employment Status 0.030
Unemployed 95 65.5% 41 54.7%
Student 3 2.1% 9 12.0%
Permanent 25 17.2% 13 17.3%
Casual/Self Employed 22 15.2% 12 16.0%
Repeated a grade in school 0.910
No 117 80.7% 61 81.3%
Yes 28 19.3% 14 18.7%
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Logistic regression analysis (see Table 4) showed that
there were no statistically significant differences in cog-
nitive impairment with age (p = 0.77), number of months
since diagnosis (p = 0.90) number of months since ART
initiation (p = 0.44), marital status (p = 0.24), employ-
ment status (p = 0.16) and repeating a grade in school
(p = 0.34) suggesting no statistically significant associ-
ation of these factors with cognitive impairment. How-
ever, odds ratios gradually increased with the increase in
age of the participant, unemployment and time since
diagnosis suggesting that the odds of cognitive impair-
ment increase with age, unemployment and time since
ART initiation. The unadjusted odds ratio showed a sta-
tistically significant association of cognitive impairment
with HIV status (positive), sex (women), and number of
years of education (less). After adjustment, the associ-
ation for HIV status remained significant (OR 2.67,
CI1.35–5.27), suggesting people living with HIV are
nearly 2.5 times more likely to have cognitive impair-
ment compared to people without HIV. For education,
the odds of having cognitive impairment decreases as
the years of education increase and this is statistically
Table 2 HIV Positive Participants Clinical Characteristics
Characteristic Median (IQR)
aCD4 count (cells/mm3) 520 (300–699)
Nadir CD4 count (cells/mm3) 250 (135–430)
Time since HIV Diagnosis (Months) 73 (30–113)
Time since ART Initiation (Months) 69 (29–107)
bAdherence Self Report Score 24.5 (21–25)
Current ART Regimen Frequency
First Line ART regimen
Stavudine/Lamivudine/Nevirapine 2%
Tenofovir/Lamivudine/Nevirapine 2%
Zidovudine/Lamivudine/Nevirapine 1%
Tenofovir/Lamivudine/Efavirenz 93%
Second Line ART regimen
Abacavir/Lamivudine/Atazanavir 2%
Medication Switched Since Initiation
Yes 30%
No 70%
Note: aMost recent CD4 count as per clinic records. bScored out of 25
Table 3 Test Performance Differences
Domain Test HIV Positive HIV Negative p-
valueMean (SD) 95% CI Mean (SD) 95% CI
Executive Function Wisconsin card sorting test total 60.4 (20.4) 57.1–63.7 61.6 (19.6) 57.1–66.0 0.680
Wisconsin card sorting test trials 53.3 (47.7) 45.7–61.0 46.1 (46.8) 35.4–56.8 0.280
Color Trails 2b 159.6 (59.0) 139.9–155.2 122.9 (42.5) 113.2–132.6 0.001
Attention Digit Span 12.1 (3.3) 12.2–13.0 13.7(2.6) 13.1–14.3 0.001
Spatial Span 8.8 (3.5) 8.2–9.3 10.9 (3.0) 10.2–11.6 0.001
PASATa 21.1 (9.3) 19.6–22.5 26.9 (12.6) 24.1–29.8 0.001
Speed of Information Processing Digit Symbol 33.3 (11.6) 31.5–35.2 43.2 (15.0) 39.8–46.7 0.001
Symbol Search 18.9 (5.7) 18.0–19.8 22.6 (7.0) 21.0–24.2 0.001
TMTAa, b 66.0 (23.0) 57.9–63.9 50.5 (16.3) 46.8–54.3 0.001
Color Trails 1b 73.8 (30.0) 68.9–78.8 59.4 (24.2) 53.9–65.0 0.001
Learning BVMTa 8.1 (4.9) 7.4–8.9 10.6 (5.4) 9.3–11.8 0.001
HVLTa 20.5 (3.3) 20.0–21.1 21.8 (3.5) 21.0–22.6 0.007
Memory BVMTa Recall 3.4 (2.2) 3.0–3.8 4.5 (2.5) 4.0–5.0 0.001
HVLTa Recall 6.2 (1.9) 5.9–6.5 6.9(1.9) 6.5–7.3 0.009
Motor Function Grooved pegboard nondominantb 104.0 (25.8) 99.9–108.1 91.8 (23.3) 86.5–97.2 0.001
Grooved Pegboard dominantb 91.6 (31.4) 86.6–96.6 80.6 (23.2) 75.3–85.9 0.008
Successive Finger Tapping non dominantb 11.0 (5.0) 10.2–11.8 11.9 (8.2) 10.1–13.8 0.280
Successive Finger Tapping dominantb 11.1 (5.0) 10.3–11.9 10.8 (3.8) 10.0–11.7 0.650
Verbal Fluency Fruit and Vegetable List 12.7 (3.6) 12.1–13.2 14.0 (3.2) 13.2–14.7 0.001
Animal List 13.2 (3.2) 12.7–13.7 14.6 (3.2) 13.9–15.3 0.002
aAbbreviations: PASAT-Paced Auditory Serial Addition Test; TMT A-Trail Making Test Part A; BVMT-Brief Visuospatial Memory test; HVLT-Hopkins Verbal Learning Test;
bHigher scores indicate worse performance
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significant (p = 0.002) suggesting the more years of edu-
cation one has, the decreased odds there are of having
cognitive impairment. The association for sex was no
longer statistically significant after adjustment (p = 0.28)
suggesting that the association with sex is no longer sta-
tistically significant after controlling for other factors.
A one way ANOVA analysis (Table 5) showed that
mean GDS was different based on education such that
less education was significantly related to worse GDS
scores and more education related to better GDS scores,
but age was not.
Discussion
To our knowledge this is the first study to assess NCI
using a comprehensive NP battery in adults living with
HIV attending primary care clinics in Zimbabwe and
highlight the prevalence of NCI. In this sample of treat-
ment experienced adults living with HIV the NCI preva-
lence of 49.7% found in this study is still very high
especially in this era of highly active antiretroviral ther-
apy. This finding is however consistent with studies that
have been conducted in the United States) [12].
Global deficit scores were used to indicate neurocogni-
tive impairment in this study. In other studies in sub-
Saharan Africa that have used the GDS scoring method
the prevalence in Zambia was 35% [13] 38% in Uganda
[15] and in Malawi 16% based on GDS of 1 and above
[14]. The prevalence in our study was much higher com-
pared to these prior reports in the literature. While age
was not perfectly matched between groups, we note that
most participants were under 40 years of age an age that
is less associated with abnormal cognitive decline in the
general population [42].
Several factors are known to be associated with
NCI including older age and lower education [4, 43].
In this study, the odds of NCI increased with age al-
though this is not statistically significant. People living
with HIV are living longer and in the POPPY Study
they found an NCI prevalence of 35% [44] . NCI in
older age could be due to the normal process of
aging and more attention is needed for this older
population. The association of NCI with education in
this setting remained statistically significant after ad-
justment and this is in line with a recent study in
sub-Saharan Africa [45]. Attention and memory were
the most impaired domains. This is consistent with
data from a qualitative study where HIV-positive pa-
tients reported increased difficulties with attention
and memory affecting their day to day activities [46,
47]. Deficits in these domains also affect medication
adherence and compliance with clinic appointments
[47]. As medication adherence is key in achieving
viral suppression, this is an area where interventions
are required.
The advent of cART resulted in a decline of NCI but
in this study, the prevalence in adults on cART is still
very high. This could be because the majority of partici-
pants in this study were on an efavirenz (EFV) based
Fig. 1 NCI in HIV-Positive Patients
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regimen. Previous studies have shown increased NCI in
people on an EFV based regimen [14, 48, 49]. This is the
first line treatment given to adults living with HIV in
Zimbabwe. However, the World Health Organisation re-
cently recommended the use of dolutegravir instead of
efavirenz as part of the first line regimens [50]. With the
introduction of the newer ART drugs, the effects of the
old ones including possible cognitive deficits needs to be
considered.
These study findings should be interpreted in light
of some limitations. Firstly, the absence of some real
time information on viral loads and CD4 counts of
Table 4 Logistic Regression
Total Univariable analysis Adjusted Analysis
N % OR 95% Cl p-value OR 95% Cl p-value
HIV status 0.001* 0.005
Negative 76 32.9% 1.00 1.00
positive 155 67.1% 3.70 1.96–6.99 2.67 1.35–5.27
Sex 0.040* 0.277
Male 46 29.7% 0.48 0.24–0.97 0.70 0.37–1.32
Female 109 70.3% 1.00 1.00
Education 0.040* 0.002
7 years 30 19.4% 1.00 1.00
8 to 10 years 52 33.6% 0.40 0.15–1.03 0.40 0.19–1.05
11–13 years 62 40.0% 0.38 0.15–0.95 0.35 0.16–0.79
14 and above 11 7.1% 0.10 0.17–0.53 0.05 0.10–0.25
Age 0.700
18–25 31 20.0% 1.00
26–45 82 52.9% 1.16 0.51–2.65
46 and above 42 27.1% 1.47 0.57–3.73
Time since ART Initiation 0.440
6 months and less 15 9.8% 1.00
7 to 24 months 19 12.4% 0.88 0.29–3.52
25 to 48 months 22 14.4% 1.25 0.33–4.73
49months and above 97 63.4% 1.77 0.59–5.37
Time Since Diagnosis 0.900
6 months and less 13 8.6% 1.00
7 to 24 months 21 13.9% 0.64 0.16–2.58
25 to 48 months 19 12.6% 0.77 0.19–3.17
49months and above 98 64.9% 0.89 0.28–2.85
Marital Status 0.240
Divorced/Widowed 47 30.3% 1.00
Married/Partner 62 40.0% 0.98 0.46–2.10
Single 34 21.9% 0.50 0.20–1.23
Repeated Grade 0.340
No 117 75.5% 1.00
Yes 28 18.1% 0.67 0.29–1.53
Employment Status 0.160
Permanent 25 16.1% 1.00
Self Employed 22 14.2% 1.23 0.38–4.00
Student 3 1.94% 0.88 0.07–11.22
Unemployed 95 61.3% 2.44 0.98–1.27
*Statistically significant factors (i.e. <= 0.05) in the logistic regression model were adjusted for
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the participants at the time they presented for testing.
Patients are supposed to have annual viral load and
CD4 count tests, but this was not the case at these
primary care clinics. This would have provided rich
clinical data and interpretation of the neuropsycho-
logical battery results would be informed by current
immunological and clinical functioning information.
Secondly, the participants were not perfectly matched
for age, education and sex. The primary care clinics
where participants were recruited have an initiative to
test people for HIV and these are the participants
who had frequent visits to the clinic. They were
younger and had more years of education. This made
the recruitment of matched participants for compari-
sons harder. We recognise that the small number of
participants with tertiary education might inflate the
impairment somewhat, however, it is unlikely that it
will account for a large percentage of the impairment
considering most of the HIV-positive patients com-
pleted high school education which is indicated in
Table 1 as 11–13 years which means most had a good
level of education.
Future research should include objective biomarkers
for CD4 and viral load that can be used to ascertain any
relationship between clinical functioning and NCI. It is
important to have norms available carefully selected for
age, sex and education. These are key in NCI research
and more research is needed in this area.
Conclusion
By exploring the prevalence of NCI in primary care
clinics where the majority of the patients in
Zimbabwe are seen, we now know the extent of the
NCI burden in our setting. It is therefore important
for us to come up with effective ways of routinely
screening for NCI and develop interventions specific
to the cognitive domains affected. This will be im-
portant to improve activities of daily living and pos-
sibly adherence to medication for people with NCI.
NCI is largely neglected, and it is high time it is
given the importance it deserves because of the ad-
verse effects it has.
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